NATUS MEDICAL INCORPORATED

(NTUS)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
32.65 USD   +1.15%
06/15NATUS MEDICAL INC : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
05/17NATUS MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA : Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Natus Medical Incorporated - NTUS
BU
05/06NATUS MEDICAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NATUS MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Natus Medical Incorporated - NTUS

05/17/2022 | 10:40am EDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Natus Medical Incorporated (NasdaqGS: NTUS) to an affiliate of ArchiMed. Under the terms of the proposed transaction, shareholders of Natus will receive only $33.50 in cash for each share of Natus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-ntus/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.


© Business Wire 2022
All news about NATUS MEDICAL INCORPORATED
06/15NATUS MEDICAL INC : Submission of Matters to a Vote of Security Holders, Financial Stateme..
AQ
05/17NATUS MEDICAL INVESTOR ALERT BY THE : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
05/06NATUS MEDICAL INC Management's Discussion and Analysis of Financial Condition and Resu..
AQ
05/05NATUS MEDICAL INVESTOR ALERT BY THE : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
05/05NATUS MEDICAL : Q1 Earnings Snapshot
AQ
05/05Earnings Flash (NTUS) NATUS MEDICAL INCORPORATED Reports Q1 EPS $0.22, vs. Street Est o..
MT
05/05Natus Medical Q1 Non-GAAP EPS, Revenue Rise
MT
05/05Natus Medical Incorporated Reports Earnings Results for the First Quarter Ended March 3..
CI
05/05Natus Medical Announces First Quarter 2022 Financial Results
AQ
04/19CORRECTION : Sector Update: Health Care Stocks Stumble Monday Afternoon
MT
More news
Financials (USD)
Sales 2022 495 M - -
Net income 2022 34,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 32,6x
Yield 2022 -
Capitalization 1 105 M 1 105 M -
Capi. / Sales 2022 2,23x
Capi. / Sales 2023 2,14x
Nbr of Employees 1 400
Free-Float 98,1%
Chart NATUS MEDICAL INCORPORATED
Duration : Period :
Natus Medical Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NATUS MEDICAL INCORPORATED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 32,28
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Thomas J. Sullivan President, Chief Executive Officer & Director
Benjamin Drew Davies Chief Financial Officer & Executive Vice President
Joshua H. Levine Non-Executive Chairman
Ivan Pandiyan Senior Director-Research & Development
Seán Langan Vice President-Global Operations
Sector and Competitors